一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Epcoritamab；Cyclophosphamide；Rituximab；Vincristine；Doxorubicin；Prednisone，当前状态为研究进行中，已停止招募。登记地点显示中国北京、福州、厦门、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Epcoritamab；Cyclophosphamide；Rituximab；Vincristine；Doxorubicin；Prednisone · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Fifth Medical Center of PLA General Hospital /ID# 230941 · 北京
- Beijing Cancer Hospital /ID# 229819 · 北京
- Peking University Third Hospital /ID# 230975 · 北京
- Fujian Provincial Cancer Hospital /ID# 238430 · 福州
- The First Affiliated Hospital of Xiamen University /ID# 238426 · 厦门
- Sun Yat-Sen University Cancer Center /ID# 238371 · 广州
- Guangdong Provincial People's Hospital /ID# 230945 · 广州
- Nanfang Hospital of Southern Medical University /ID# 238436 · 广州
- Fourth Hospital of Hebei Medical University /ID# 238656 · 石家庄
- Harbin Medical University Cancer Hospital /Id# 241755 · 哈尔滨
- Henan Cancer Hospital /ID# 230398 · 郑州
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 234152 · 武汉
- Hubei Cancer Hospital /ID# 232256 · 武汉
- The First Affiliated Hospital of Soochow University /ID# 232569 · 苏州
- The Affiliated Hospital of Xuzhou Medical College /ID# 233174 · 徐州
- The First Affiliated Hospital of Nanchang University /ID# 230399 · 南昌
- Jiangxi Provincial Cancer Hospital /ID# 233379 · 南昌
- The First Hospital of Jilin University /ID# 239618 · 长春
- The First Hospital of China Medical University /ID# 233201 · 沈阳
- Shandong Cancer Hospital /ID# 233200 · 济南
- Fudan University Cancer Hospital /ID# 251516 · 上海
- Shanxi Provincial Cancer Hospital /ID# 250745 · 太原
- Tianjin Cancer Hospital /ID# 230974 · 天津
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 259904 · 天津
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 230387 · 杭州
- The second affiliated hospital of Zhejiang University school of medicine /ID# 231249 · 杭州
- Zhejiang Cancer hospital /ID# 231388 · 杭州
公开的入选条件
- * Planned to receive treatment with 6 cycles of standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) per investigator determination.
- * Must have newly diagnosed, histologically confirmed CD20+ diffuse large b-cell lymphoma \[DLBCL\] (de novo or histologically transformed from a diagnosis of follicular lymphoma) at most recent representative tumor biopsy based on the pathology report, with a
- DLBCL, Not Otherwise Specified (NOS).
- High grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangement with DLBCL morphology.
- T-cell/histiocyte-rich large B-cell lymphoma.
- Epstein Barr virus-positive DLBCL, NOS.
- Follicular lymphoma Grade 3b.
- Note: The local pathology report must be available at Screening to support CD20+ DLBCL histology.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05578976；登记信息更新于 2026-09-11。